FierceBiotech Mar 17, 2026 Hitting regulatory roadblock, Bicycle pumps brakes on lead program and deflates headcount by 30%
FierceBiotech Mar 17, 2026 BioVie plans $20M IPO for spinout tasked with developing liver disease drug
FierceBiotech Mar 17, 2026 R1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment
FierceBiotech Mar 17, 2026 Roche inks Nvidia deal to bolster AI factory, speed up drug and diagnostic development
FierceBiotech Mar 16, 2026 Astellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 years
FierceBiotech Mar 13, 2026 Sana sees 14-month insulin production for transplanted islet therapy in single Type 1 diabetes patient
FierceBiotech Mar 13, 2026 China approves first brain-computer interface implant for paralyzed patients, as sector heats up
FierceBiotech Mar 13, 2026 Stop Asking for an AI strategy: 3 questions clinical leaders should ask instead
FierceBiotech Mar 12, 2026 Vistagen lays off 20% of staff to tighten focus on struggling social anxiety candidate
FierceBiotech Mar 12, 2026 Pfizer Ignite, designed to accelerate promising biotech therapies, fizzles out
FierceBiotech Mar 12, 2026 Fledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program